Takeda has pulled back from a research collaboration with a fellow Japanese life sciences company, ending work to discover ...

Astellas is preparing to close the Seattle site of its stem cell therapy unit, with around 55 employees set to be impacted. | ...

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

Click Therapeutics is cutting staff just days after announcing a new funding round and taking over commercial work for its ...

Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy ...

Kazia Therapeutics is paying $1.4 million upfront to secure a platform for generating epigenetic drugs from an Australian research institute. Brisbane-based QIMR Berghofer develop ...

Harbinger Health has grabbed $100 million in its latest funding round as the company reveals a new Resolve in its cancer ...

Stryker is picking up vascular devices maker Amplitude Vascular Systems while Avanos Medical is being taken private in a ...

Californian protein sequencing company Alamar Biosciences is seeking an IPO worth up to $159 million amid a growing boom in ...

Kailera is taking another step into the competitive obesity market by aiming to raise up to $528.5 million via a Nasdaq IPO, ...

An FDA review of records in the U.S. clinical trials database shows that results have not been reported for 30% of clinical ...

Spyre Therapeutics’ monoclonal antibody hit the key goal of a phase 2 study in ulcerative colitis (UC), which the company has touted as proof it can best Takeda’s Entyvio. The mid-stage trial ...